Showing results (121-130 of 143) with videos related to
Sort By:
Pageof 15
Drug Safety|May 29, 2019
Cardiovascular Safety of Prucalopride in Patients with Chronic Constipation: A Multinational Population-Based Cohort StudyAlicia Gilsenan, Joan Fortuny, Miguel Cainzos-Achirica, et al.American Journal of Hypertension|May 21, 2025
Low Achieved Systolic Blood Pressure Related to Kidney Protection in Diabetic and Non-Diabetic High-Risk Hypertensive PatientsEirik Olsen, Camilla L Søraas, Roland E Schmieder, et al.Journal of Hypertension|June 24, 2006
Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trialSverre E Kjeldsen, Stevo Julius, Giuseppe Mancia, et al.BMJ (Clinical Research Ed.)|February 25, 2021
Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trialsEmily Herrett, Elizabeth Williamson, Kieran Brack, et al.Lancet (London, England)|October 14, 2022
Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trialIsla S Mackenzie, Amy Rogers, Neil R Poulter, et al.Pharmacoepidemiology and Drug Safety|January 2, 2021
Impact of EMA regulatory label changes on hydroxyzine initiation, discontinuation and switching to other medicines in Denmark, Scotland, England and the Netherlands: An interrupted time series regression analysisDaniel R Morales, Tatiana Macfarlane, Thomas M MacDonald, et al.JAMA|August 23, 2012
Lipid-modifying therapies and risk of pancreatitis: a meta-analysisDavid Preiss, Matti J Tikkanen, Paul Welsh, et al.Atherosclerosis. Supplements|February 16, 2021
The prevalence of cardiovascular risk factors and cardiovascular disease among primary care patients in Poland: results from the LIPIDOGRAM2015 studyJacek J Jóźwiak, Krzysztof Studziński, Tomasz Tomasik, et al.British Journal of Clinical Pharmacology|July 16, 2020
Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysisDaniel R Morales, Steven V Morant, Thomas M MacDonald, et al.Pharmacoepidemiology and Drug Safety|January 4, 2020
Impact of EMA regulatory label changes on systemic diclofenac initiation, discontinuation, and switching to other pain medicines in Scotland, England, Denmark, and The NetherlandsDaniel R Morales, Steve V Morant, Thomas M MacDonald, et al.Pageof 15